Clinical Trials Logo

Clinical Trial Summary

A single-arm, open, multicenter study to investigate the efficacy and safety of YY-20394, an oral small molecular inhibitor of PI3K-delta, in patients with relapsed or refractory peripheral T/NK cell lymphoma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04705090
Study type Interventional
Source Shanghai YingLi Pharmaceutical Co. Ltd.
Contact Hanying Bao, MD,PhD
Phone 86 21-51370693
Email hybao@yl-pharma.com
Status Not yet recruiting
Phase Phase 2
Start date April 2021
Completion date June 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03900442 - Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort Phase 1
Withdrawn NCT02757248 - Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL Phase 1
Not yet recruiting NCT05238064 - Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL Phase 1/Phase 2
Recruiting NCT03240211 - Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL Phase 1
Recruiting NCT04747236 - Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL Phase 2
Completed NCT03493451 - Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Phase 2
Recruiting NCT05967949 - A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.
Recruiting NCT03884205 - GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL